News 12.04.2023 BERLIN, Germany and ZURICH, Switzerland, April 12, 2023 / B3C newswire / -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial...
News 15.03.2023 Schlieren (Zurich), Switzerland, March 15, 2023 – Kuros Biosciences today announces continued robust progress with its results for full year 2022, increasing MagnetOs direct sales by 75% and completing enrollment of the randomized stage of the Phase 2 spine study for Fibrin-PTH, confirming its successful transition into a fully-fledged orthobiologics...
Events, External events
Event date: 12.12.2023
Come and join us for the 12th edition of BioFIT, on December 12th & 13th, 2023 in Marseille and online on December 15th!
With the highest attending rate of TTOs, research institutes and academia together with big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors,...
News 10.03.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, today announced its corporate highlights and audited financial results...
News 09.03.2023 Zurich-Schlieren, Switzerland, March 9, 2023. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new results evaluating Proclarix® in combination with imaging were published in BJU International[1]. The early detection of clinically significant prostate cancer decreases prostate cancer mortality. The use of multiparametric magnetic resonance imaging...